Question · asked by 1 review
Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy): Adverse effects
- Population
- People with squamous cell carcinoma of the oral cavity or oropharynx
- Intervention
- Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy)
- Comparison
- Standard therapy alone (radiotherapy or chemoradiotherapy)
- Outcome
- Adverse effects
Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… led to higher adverse effects compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported.
What each review found
Include earlier review versionsNo studies found 0 · 0%GRADE not reported 9 · 100%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy) Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx · 40 to 60 months, Skin toxicity (lapatinib, all grades) Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… led to higher adverse effects compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy (2015) · Cochrane All outcomes | RR 2.02 [1.23, 3.32] | 1 study · 67 participants | GRADE not reported |
Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy) Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx · 40 to 60 months, Gastrointestinal complaints (gefitinib, all grades) Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… showed no clear difference in adverse effects compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy (2015) · Cochrane All outcomes | RR 1.04 [0.98, 1.11] | 1 study · 226 participants | GRADE not reported |
Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy) Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx · 40 to 60 months, Gastrointestinal complaints (lapatinib, all grades) Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… led to higher adverse effects compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy (2015) · Cochrane All outcomes | RR 15.53 [2.18, 110.55] | 1 study · 67 participants | GRADE not reported |
Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy) Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx · 40 to 60 months, Skin toxicity (erlotinib, all grades) Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… led to higher adverse effects compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy (2015) · Cochrane All outcomes | RR 6.57 [3.60, 12.00] | 1 study · 191 participants | GRADE not reported |
Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy) Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx · 40 to 60 months, Mucositis (grades >=3) Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… showed no clear difference in adverse effects compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy (2015) · Cochrane All outcomes | RR 1.22 [0.96, 1.56] | 2 studies · 286 participants | GRADE not reported |
Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy) Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx · 40 to 60 months, Mucositis (all grades) Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… showed no clear difference in adverse effects compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy (2015) · Cochrane All outcomes | RR 1.03 [0.94, 1.11] | 2 studies · 286 participants | GRADE not reported |
Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy) Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx · 40 to 60 months, Skin toxicity (gefitinib, all grades) Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… showed no clear difference in adverse effects compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy (2015) · Cochrane All outcomes | RR 1.03 [0.82, 1.28] | 2 studies · 286 participants | GRADE not reported |
Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy) Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx · 40 to 60 months, Gastrointestinal complaints (grades >=3, pooled) Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… showed no clear difference in adverse effects compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy (2015) · Cochrane All outcomes | RR 1.11 [0.83, 1.49] | 3 studies · 484 participants | GRADE not reported |
Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy) Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx · 40 to 60 months, Skin toxicity (grades >=3, pooled) Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… showed no clear difference in adverse effects compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy (2015) · Cochrane All outcomes | RR 1.25 [0.54, 2.88] | 4 studies · 544 participants | GRADE not reported |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes | 2015-02 | Not listed | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.